Familial Nasopharyngeal Carcinoma 6

Screening and Early Diagnosis of Nasopharyngeal Carcinoma 63screening test for patients with nasopharyngeal carcinoma.Biotechnol Appl Biochem 47:59–69IARC monographs on the evaluation of carcinogenic risks tohumans (1997) Epstein–Barr virus and Kaposi’s sarcomaherpesvirus/human herpesvirus 8, Vol. 70. IARC Press,Lyon, France, pp 47–373Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, Zong YS,Chan KH, Ng SP, Wei WI, Chua DT, Sham JS, et al. (2007)Sustained elevation of Epstein–Barr virus antibody levelspreceding clinical onset of nasopharyngeal carcinoma. BrJ Cancer 96:623–630Lanier AP, Bornkamm GW, Henle W, Henle G, Bender TR,Talbot ML, Dohan PH (1981) Association of EBV with NPCin Alaskan native patients: serum antibodies and tissueEBNA and DNA. Int J Cancer 28:301–305Lee N, Xia P, Quivey JM, et al. (2002) Intensity-modulatedradiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience. Int J Radiat OncolBiol Phys 53(1):12–22Lennette ET, Winberg G, Yadav M, Enbald G, Klein G (1995)Antibodies to LMP2A/2B in EBV-carrying malignancies.Eur J Cancer 31:1875–1878Leung SF, Tam JS, Chan AT, Zee B, Chan LY, Huang DP, VanHasselt A, Johnson PJ, Lo YM (2004) Improved accuracy ofdetection of nasopharyngeak carcinoma by combinedapplication of circulation Epstein–Barr virus DNA andanti-Epstein Barr virus casid antigen IgA antibody. ClinChem 50:339–345Lin S, Pan J, Lu H, et al. (2009) Nasopharyngeal carcinomatreated with reduced-volume intensity-modulated radiationtherapy: report on the 3-year outcome of a prospectiveseries. Int J Radiat Oncol Biol Phys 2009 Apr 11 [Epub aheadof print]Lin SY, Tsang NM, Kao SC, Hsieh YL, Chen YP, Tsai CS, Kuo TT,Hao SP, Chen IH, Hong JH (2001) Presence of Epstein–Barrvirus latent membrane protein 1 gene in the nasopharyngealswabs from patients with nasopharyngeal carcinoma.Head Neck 23:194–200Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS, Jiang RS(2004) Quantification of plasma Epstein-Barr virus DNA inpatients with advanced nasopharyngeal carcinoma. N englJ Med 350:2461-70Lin TM, Yang CS, Chiou JF, Tu SM, Chen TY, Tu YC, Lin PJ,Kawamura A Jr, Hirayama T (1977) Antibodies to Epstein–Barr virus capsid antigen and early antigen in nasopharyngealcarcinoma and comparison groups. Am J Epidemiol106:336–339Liu MY, Chang YL, Ma J, Yang HL, Hsu MM, Chen CJ, Chen JY,Yang CS (1997) Evaluation of multiple antibodies toEpstein–Barr virus as markers for detecting patients withnasopharyngeal carcinoma. J Med Virol 52:262–269Lo KW, Lo YMD, Leung SF, Tsang YS, Chan LY, Johnson PJ,Hjelm NM, Lee JC, Huang DP (1999a) Analysis of cell-freeEpstein–Barr virus associatedRNAin the plasma of patientswith nasopharyngeal carcinoma. Clin Chem 45: 1292–1294Lo YMD, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC,Hjelm NM, Johnson PJ, Huang DP (1999b) Quantitativeanalysis of cell-free Epstein–Barr virus DNA in plasma ofpatients with nasopharyngeal carcinoma. Cancer Res9:1188–1191Lo YMD, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC,Hjelm NM, Johnson PJ, Huang DP (1999c) Quantitative andtemporal correlation between circulating cell-free Epstein–Barr virus DNA and tumour recurrence in nasopharyngealcarcinoma. Cancer Res 59:5452–5455Lung ML, Chang GC (1992) Detection of distinct Epstein–Barrvirus genotypes in NPC biopsies from southern Chineseand Caucasians. Int J Cancer 52:34–37Lynn TC, Hsu MM, Hsieh T, Tu SM, Hamajima K (1976)Nasopharyngeal carcinoma and Epstein–Barr virus. III.The detection of anti-nuclear antibodies. Jpn J Exp Med46:289–295Mutirangura A, Pornthanakasem W, Theamboonlers A,Sriuranpong V, Lertsanguansinchi P, Yenrudi S, Voravud N,Supiyaphun P, Poovorawan Y (1998) Epstein–Barr viralDNA in serum of patients with nasopharyngeal carcinoma.Clin Cancer Res 4:665–669Ng WT, Yau TK, Yung RWH, Sze WM, Tsang AHL, Law ALY,Lee AWM (2005) Screening for family members of patientswith nasopharyngeal carcinoma. Int J Cancer 113:998–1001Niedobitek G (2000) Epstein–Barr virus infection in the pathogenesisof nasopharyngeal carcinoma. Mol Pathol 53:248–254Niedobitek G, Young LS, Sam CK, Brooks L, Prasad U, RickinsonAB (1992) Expression of Epstein–Barr virus genes and oflymphocyte activation molecules in undifferentiatednasopharyngeal carcinomas. Am J Pathol 140:879–887Raab-Traub N (2002) Epstein–Barr virus in the pathogenesisof NPC. Semin Cancer Biol 12:431–441Reddi KK, Holland JF (1976) Elevated serum ribonuclease inpatients with pancreatic cancer. Proc Natl Acad Sci USA73:2308–2310Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF,Ernberg I, Zeng YX (2004) Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulinA/virus capsid antigen antibody titers in patients withnasopharyngeal carcinoma. Cancer 100:1162–1170Sheen TS, Ko JY, Chang YL, et al. (1998) Nasopharyngeal swaband PCR for the screening of nasopharyngeal carcinoma inthe endemic area: a good supplement to the serologicscreening. Head Neck 20:732–738Shotelersuk K, Khorprasert C, Sakdikul S, Pornthanakasem W,Voravud N, Mutirangura A (2000) Epstein–Barr virus DNAin serum/plasma as a tumour marker for nasopharyngealcancer. Clin Cancer Res 6:1046–1051Tang JW, Rohwäder E, Chu IM, Tsang RK, Steinhagen K, YeungAC, To KF, Chan PKJ (2007) Evaluation of Epstein–Barrvirus antigen-based immunoassays for serological diagnosisof nasopharyngeal carcinoma. J Clin Virol 40:284–288Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA(2004) Sensitivity and specificity of Epstein–Barr virusIGA titer in the diagnosis of nasopharyngeal carcinoma:a three-year institutional review. Head Neck 26:598–602Wara WM, Wara DW, Phillips TL, Ammann AJ (1975) ElevatedIgA in carcinoma of the nasopharynx. Cancer 35:1313–1315Williams EH, de The G (1974) Letter: familial aggregation innasopharyngeal carcinoma. Lancet 2:295–296Wu TC, Mann RB, Epstein JI, et al. (1991) Abundant expressionof EBER1 small nuclear RNA in nasopharyngeal carcinoma.Am J Pathol 138:1461–1469